Core Viewpoint - BD (Becton, Dickinson and Company) will host an audio webcast on February 9, 2026, to discuss its financial results for Q1 of fiscal year 2026 and provide updates on operations and strategy [1]. Group 1: Company Overview - BD is one of the largest global medical technology companies, focused on improving medical discovery, diagnostics, and care delivery [2]. - The company employs over 70,000 individuals and is committed to enhancing the safety and efficiency of healthcare delivery [2]. - BD collaborates with organizations worldwide to tackle significant global health challenges, aiming to improve outcomes, lower costs, and expand access to healthcare [2]. Group 2: Upcoming Financial Discussion - The audio webcast will be accessible on BD's investor relations website, with a replay available shortly after the call [1]. - Prior to the webcast, BD will issue a news release and presentation materials containing summary financial information for the quarter [1].

Core Viewpoint - Waters Corporation has received overwhelming shareholder approval for the issuance of shares to Becton, Dickinson and Company in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with the transaction expected to close on February 9, 2026 [1][2][3] Group 1: Shareholder Approval and Transaction Details - Approximately 99% of shares present at the Special Meeting voted in favor of the share issuance to BD shareholders [3] - The transaction has received all required regulatory approvals and a favorable Private Letter Ruling from the IRS regarding U.S. federal income tax consequences [2] - The expected closing date for the transaction is February 9, 2026, subject to customary closing conditions [2] Group 2: Future Outlook and Company Vision - The company aims to create meaningful value for patients, customers, employees, and shareholders as it transitions into a leader in life sciences and diagnostics [2] - The upcoming Q4 2025 financial results will be released on February 9, 2026, coinciding with the expected transaction close [4] - Waters Corporation has been a global leader in analytical instruments and technologies for over 65 years, serving various scientific fields [5]

Core Viewpoint - BD (Becton, Dickinson and Company) is set to spin off its Biosciences & Diagnostic Solutions business to shareholders, followed by a merger with Waters Corporation, with the transaction expected to close on February 9, 2026 [1][2]. Transaction Details - The transaction will involve BD receiving $4 billion in cash, while BD shareholders will obtain 39.2% of the combined company on a fully diluted basis, with existing Waters shareholders owning 60.8% [2]. - BD shareholders do not need to take any action other than holding their shares as of the record date to receive Waters common stock [3]. - Following the transaction, BD shareholders will retain the same number of BD shares they held prior to the transaction [3]. Regulatory and Approval Status - BD has received a favorable Private Letter Ruling from the IRS regarding the U.S. federal income tax implications of the transaction, and Waters shareholders have approved the issuance of shares in the merger [4]. - The transaction is subject to customary closing conditions [4]. Trading Information - From February 5, 2026, BD common stock will trade with "due bills" representing the right to receive the SpinCo common stock distribution, which will convert into shares of Waters common stock upon closing [5]. - After the transaction closes, BD common stock is expected to be quoted "Ex-Distribution," meaning it will no longer include the entitlement to receive the SpinCo common stock distribution [5].

Core Insights - Becton, Dickinson and Company (BDX) is expanding its partnership with Ypsomed to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe, aimed at meeting the growing demand for large-volume subcutaneous self-injection [2][3][4] Company Developments - The new 5.5 mL syringe is designed for full compatibility with Ypsomed's YpsoMate 5.5 autoinjector, enhancing the ease of use for patients requiring high-dose biologic medicines [3][4] - The syringe features advanced technology, including a shorter 8-millimeter needle and thinner cannula walls, to improve flow and reduce injection time, addressing common issues with large-volume biologics [9][8] - The partnership aims to strengthen BD's competitive positioning in drug delivery systems, particularly as biologics pipelines shift toward higher-dose, subcutaneous formulations [6][4] Market Trends - The prefilled syringes market is projected to reach $24.13 billion by 2026, with a CAGR of 11.6% through 2035, driven by the rising demand for safe and convenient drug delivery systems and the increasing use of biologics and injectable therapies [13] Financial Performance - Following the announcement of the partnership, BDX shares increased by 1.4%, with a 13.7% rise over the past six months, slightly below the industry growth of 13.9% and the S&P 500's 10.4% increase [5]

Core Insights - Becton, Dickinson and Company (BDX) has received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, expected to launch in early 2026, aimed at enhancing flexibility in breast disease diagnosis [1][9] Company Developments - The FDA clearance reflects BD's commitment to addressing the evolving needs of clinicians and patients in breast health, emphasizing versatility and precision in the new system [2] - The EnCor EnCompass Biopsy System is designed to support early detection and diagnosis of breast disease, aligning with BD's long-term strategy of transforming care through innovation [3] - The system features multi-modality capabilities, adjustable vacuum strengths, and enhanced visualization tools, which are intended to improve workflow efficiency and patient experience [11][12] Market Position and Financials - BDX's market capitalization stands at $59.01 billion [7] - Following the announcement, BDX shares have decreased by 2.4%, while the company has seen a 16% increase in share price over the past six months, compared to the industry's 17.8% growth and the S&P 500's 12.8% rise [4] Industry Prospects - The global breast biopsy devices market is projected to reach $1.13 billion by 2025, with a CAGR of 4.2% through 2034, driven by rising breast cancer incidence and increased awareness [13]

LE PONT-DE-CLAIX, France and BURGDORF, Switzerland, Jan. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopakâ"¢ XtraFlowâ"¢ Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, expanding options for pharmaceutical comp ...

Core Viewpoint - Invesco is an independent investment management firm focused on enhancing the investment experience for individuals [1] Group 1 - Invesco emphasizes the importance of understanding investment objectives, risks, charges, and expenses before making investment decisions [1] - The firm provides educational content but does not offer specific investment recommendations or tax advice [1] - Invesco's investment opinions are based on current market conditions and may change without notice [1] Group 2 - Invesco Distributors, Inc. serves as the US distributor for Invesco Ltd.'s retail products and collective trust funds [1] - Invesco Advisers, Inc. and other affiliated investment advisers provide advisory services without selling securities [1] - Invesco Unit Investment Trusts are distributed by Invesco Capital Markets, Inc. and other broker-dealers [1]

Core Insights - The U.S. FDA has granted 510(k) clearance for Becton, Dickinson and Company's new breast biopsy system, the EnCor EnCompass, expected to launch in early 2026 [1][2] Product Overview - The EnCor EnCompass system features advanced capabilities such as high and low vacuum strengths, 360-degree sampling ability, and customizable probes for different lesion types [2] Market Valuation and Performance - Becton, Dickinson maintains a market capitalization of $59.10 billion, with a 52-week stock price range of $162.29 to $251.99 [3] - The stock is currently up 0.25% at $207.90, aligning with broader market gains, as the S&P 500 is up 0.50% [3][10] Earnings Forecast and Analyst Ratings - Analysts forecast earnings per share of $2.82, down from $3.43 in the same quarter last year, and revenue of $5.15 billion, slightly down from $5.17 billion [4] - The consensus rating among analysts is "Buy," with an average price target of $245.93, indicating the stock may be trading at a premium [4] Technical Analysis - The Relative Strength Index (RSI) is at 66.21, indicating neutral to bullish momentum [7] - The MACD shows bullish momentum with a value of 2.94, indicating the MACD line is above the signal line [7] - Key support level is at $188.50 and resistance level is at $208 [7] Momentum and Value Assessment - The Benzinga Edge score indicates a "High-Flyer" setup, with a momentum score of 35.35 confirming positive trends, but a low value score of 24.16 suggests the stock is priced for perfection [5][8] ETF Impact - Becton, Dickinson has notable weights in key ETFs, including T. Rowe Price Capital Appreciation Equity ETF (2.94%), iShares US Medical Devices ETF (4.44%), and Kovitz Core Equity ETF (4.20%) [9]

Core Insights - BD has received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, which is set to launch in early 2026, marking a significant advancement in breast health technology [1][2]. Product Overview - The EnCor EnCompass™ Biopsy System is designed to enhance the breast biopsy experience by allowing clinicians to perform procedures across various breast imaging platforms using a single integrated system [2][5]. - Key features include multi-modality use, adjustable vacuum strengths, 360° sampling capability, enhanced visualization tools, and a choice of probe sizes (12G, 10G, and 7G) to accommodate different lesion types [7]. Company Commitment - BD emphasizes its commitment to developing patient-centered solutions that improve early detection and diagnosis of breast diseases, reflecting its ongoing focus on addressing the needs of clinicians and patients [2][3][5]. - The company aims to enhance the safety and efficiency of care delivery while supporting clinical processes through innovative technologies [6].

Core Insights - BD (Becton, Dickinson and Company) has appointed Shawn Bevec as senior vice president of investor relations, effective January 20, 2026 [1][2] Group 1: Leadership and Strategy - Bevec will lead the communication of BD's strategic progress to investors and the financial community, focusing on initiatives that enhance shareholder value [2][3] - Vitor Roque, the interim chief financial officer, will oversee Bevec until a new CFO is appointed [2] Group 2: Bevec's Background - Bevec has extensive experience in investor relations and equity research, previously serving as vice president of investor relations at Quest Diagnostics [3] - His background includes roles as a sell-side research analyst at Deutsche Bank and Susquehanna International Group, focusing on health care services and medical devices [3] - Bevec has also worked in research and development at Pfizer and Johnson & Johnson, providing a strong scientific and operational foundation [3] Group 3: BD Overview - BD is one of the largest pure-play medical technology companies, dedicated to advancing health through innovation in medical essentials, connected care, biopharmaceutical systems, and interventional solutions [5] - The company employs over 70,000 people globally and delivers billions of products annually, positively impacting global healthcare [5] - BD collaborates closely with customers to enhance outcomes, lower costs, increase clinical efficiency, improve safety, and expand access to healthcare [5]